NIH multicenter AIDS cohort study commemorates 25 years of discovery

May 06, 2009

The longest U.S. study of people with HIV/AIDS will be honored at a 25th anniversary commemoration on May 12, 2009, at the Carnegie Institution for Science in Washington, D.C. The Multicenter AIDS Cohort Study (MACS) has significantly contributed to the scientific understanding of HIV, AIDS and the effects of antiretroviral therapy through more than 1,000 publications, many of which have guided public health policy and the clinical care of people with HIV. MACS investigators prospectively study the natural and treated history of HIV infection in thousands of homosexual and bisexual men at sites in Baltimore, Chicago, Pittsburgh and Los Angeles.

Guests will hear a keynote address by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. NIAID and the National Cancer Institute developed the MACS and have been its principal sponsors.

"The MACS has been one of the most rigorous and productive epidemiologic HIV/AIDS studies in history," says Dr. Fauci. "The MACS led key studies that linked sexual behavior to HIV transmission, determined the median period of time between HIV infection and the onset of AIDS, showed that an imbalance of T-cell types precedes AIDS, and made a multitude of other pivotal discoveries that advanced HIV/AIDS research."

An extraordinary characteristic of the MACS is its 25 years of behavioral and biological data and specimens from men who have sex with men, before and after they became infected with HIV, before and after they were diagnosed with AIDS, and before and after they began highly active antiretroviral therapy--along with data from a control group of same-aged, HIV-free men who have sex with men. Comparing these before-and-after specimens and data from HIV-infected and uninfected individuals has yielded numerous seminal discoveries, including:Since the study's inception in April 1984, the MACS has cumulatively enrolled nearly 7,000 men who have sex with men. Today, 2,525 men participate in the study, the others having died--usually from AIDS--or dropped out of the study. About half of the current participants are infected with HIV, and nearly 90 percent of that group takes antiretroviral therapy.

More than 200 investigators and staff belong to the MACS collaborative research team. Through behavioral questionnaires and the collection of biological specimens, study staff gather 8,500 separate pieces of information from each participant every six months, generating a gold mine of data and specimens for investigation. The scientific community and the public can access much of the MACS data, and study investigators actively pursue collaborations with outside researchers who propose studies of high scientific quality to the MACS leadership.

Along with Dr. Fauci, the anniversary event's guest speakers will include Jeffrey Crowley, director of the White House Office of National AIDS Policy; Christopher H. Bates, acting director of the Office of HIV/AIDS Policy at the U.S. Department of Health and Human Services; Gregg Gonsalves, an internationally renowned HIV activist; Shannon Hader, M.D., M.P.H., Director of the District of Columbia HIV/AIDS Administration; a participant from each of the four MACS sites; and Richard Kaslow, M.D., M.P.H., a MACS founding investigator. Potomac Fever, the a cappella ensemble of the Gay Men's Chorus of Washington, D.C., will provide entertainment.

The event will take place from 7:00 pm to 9:30 pm on May 12 in the Carnegie Institution for Science at 1530 P St. NW in Washington, D.C.
-end-
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

NCI conducts and supports research on HIV/AIDS and HIV-associated malignancies nationally and internationally. Information about NCI's role in studying HIV and HIV-related cancers is available at http://www.cancer.gov.

The National Institutes of Health (NIH)--The Nation's Medical Research Agency--includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIH/National Institute of Allergy and Infectious Diseases

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.